Needham Maintains Buy on Cellebrite DI, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Cikos maintains a Buy rating on Cellebrite DI (NASDAQ:CLBT) and raises the price target from $13.5 to $14.
May 24, 2024 | 9:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Cikos maintains a Buy rating on Cellebrite DI and raises the price target from $13.5 to $14.
The raised price target and maintained Buy rating from a reputable analyst are likely to positively influence investor sentiment and drive short-term price appreciation for CLBT.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100